Skip to main content
. 2017 Jan 23;32(3):522–527. doi: 10.3346/jkms.2017.32.3.522

Table 1. Demographics and clinical characteristics of the included patients with chronic exposure to HCQ.

Parameters All patients HCQ retinopathy No HCQ retinopathy P value*
No. of subjects 310 9 301 NA
No. of patients whose duration ≥ 5 yr 175 (31.3) 9 (100.0) 166 (55.1) NA
Age, yr 44.5 ± 12.4 48.7 ± 15.3 44.4 ± 12.4 0.308
Female 286 (92.3) 8 (88.9) 278 (92.4) 0.701
Body weight, kg 56.2 ± 8.5 53.0 ± 7.8 56.3 ± 8.5 0.251
BMI, kg/m2 22.3 ± 3.1 21.6 ± 3.2 22.3 ± 3.1 0.527
Duration of use, mon 71.7 ± 40.4 (range, 2–174) 108.9 ± 31.9 (range, 76–174) 70.5 ± 40.1 (range, 2–160) 0.005
Cumulative dose, g 625.5 ± 376.2 (range, 24–2,088) 952.0 ± 519.2 (range, 558–2,088) 615.1 ± 368.1 (range, 24–1,680) 0.008
Daily dose, mg 302.9 ± 83.3 284.1 ± 96.3 303.3 ± 83.1 0.495
Daily dose per real body weight, mg/kg 5.5 ± 1.8 5.6 ± 2.6 5.5 ± 1.7 0.84
No. of patients whose cumulative dose ≥ 1,000 g 44 (14.2) 2 (22.2) 42 (14.0) 0.485
No. of patients whose daily dose ≥ 6.5 mg/kg real body weight 103 (33.2) 3 (33.3) 100 (33.2) 0.841
Diagnosis of patients
 SLE 224 (72.3) 5 (55.6) 219 (72.6) NA
 Sjögren syndrome 45 (14.5) 1 (11.1) 44 (14.6) NA
 RA 32 (10.3) 3 (33.3) 29 (9.6) NA
 APLS 10 (3.2) 1 (11.1) 9 (3.0) NA
 Others 13 (4.2) 0 (0) 13 (4.3) NA
Systemic disease
 Kidney dysfunction 10 (3.2) 0 (0) 10 (3.3) NA
 Liver dysfunction 0 (0) 0 (0) 0 (0) NA

Data are shown as mean ± SD or number (%).

HCQ = hydroxychloroquine, BMI = body mass index, SLE = systemic lupus erythematosus, RA = rheumatoid arthritis, APLS = antiphospholipid antibody syndrome, NA = not applicable, SD = standard deviation.

*Mann-Whitney U test, which compared the 2 patient groups, “HCQ retinopathy” and “No HCQ retinopathy” group. Fourteen patients were diagnosed with more than 1 disease. Twelve patients were diagnosed with mixed connective tissue disease and one of them had vasculitis.